# Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia

> **NCT00381680** · PHASE3 · COMPLETED · sponsor: **Children's Oncology Group** · enrollment: 275 (actual)

## Conditions studied

- B-cell Childhood Acute Lymphoblastic Leukemia
- L1 Childhood Acute Lymphoblastic Leukemia
- L2 Childhood Acute Lymphoblastic Leukemia
- Intermediate Risk Recurrent Childhood Acute Lymphoblastic Leukemia

## Interventions

- **DRUG:** vincristine sulfate
- **DRUG:** prednisone
- **DRUG:** doxorubicin hydrochloride
- **DRUG:** pegaspargase
- **DRUG:** cytarabine
- **DRUG:** methotrexate
- **DRUG:** dexamethasone
- **DRUG:** etoposide
- **DRUG:** cyclophosphamide
- **DRUG:** leucovorin calcium
- **BIOLOGICAL:** filgrastim
- **DRUG:** asparaginase
- **DRUG:** mercaptopurine

## Key facts

- **NCT ID:** NCT00381680
- **Lead sponsor:** Children's Oncology Group
- **Sponsor class:** NETWORK
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-03
- **Primary completion:** 2016-03
- **Final completion:** —
- **Target enrollment:** 275 (ACTUAL)
- **Last updated:** 2024-03-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00381680

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00381680, "Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia". Retrieved via AI Analytics 2026-07-01 from https://api.ai-analytics.org/clinical/NCT00381680. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*